Full clinical approval requires stabilizing physiological decline rather than temporarily reducing surrogate biomarkers.
Regulators and clinicians are demanding long-term proof of stabilized physical organ function, such as glomerular filtration rates, rather than accepting transient protein reductions to grant definitive market access.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Transitioning to full regulatory approval required the sponsor to prove long-term stabilization of actual kidney function decline rather than simple biomarker reduction.
While Trutakna received accelerated approval based on a surrogate biomarker, its path to full approval depends on demonstrating stabilized kidney function through eGFR measurements.
Full regulatory approval for the IgA nephropathy drug requires demonstrating long-term preservation of actual kidney filtration capacity rather than just temporary protein reduction.
The FDA requires long-term proof of stabilized glomerular filtration rates, rather than transient protein reductions, to transition the therapy to full approval.